Cystic fibrosis (CF) is a genetic disorder that affects 1 in 2,500 people born in Australia. People with CF develop abnormal amounts of thick mucus in their lungs and digestive system, and are prone to severe bacterial infections. Excess mucus levels impair digestion and have critical impacts on lung function, blocking the airways and causing breathing difficulties. The mucus build-up promotes the growth of opportunistic pathogens (including Haemophilus influenza (NTHi)) in the airways. The major Goal of this project is to develop new treatments targeting mucus accumulation and bacterial infection in CF, to reduce disease burden and improve quality of life.
Dr Hock Tay, Dr Maximilian Plank, Dr Steven Maltby, Laureate Professor Paul Foster